Sobrevida, eficacia y seguridad de Golimumab en pacientes con Artritis Reumatoidea y Espondiloartritis: datos de una cohorte argentina

Sobrevida, eficacia y seguridad de Golimumab en pacientes con Artritis Reumatoidea y Espondiloartritis: datos de una cohorte argentina

Objetivos: golimumab ha sido aprobado para el tratamiento de pacientes con artritis reumatoidea (AR), artritis psoriásica (APs) y espondiloartritis axial. Sin embargo, los datos provenientes de nuestra región son escasos. El objetivo de este estudio fue evaluar la eficacia, seguridad y sobrevida ac...

Full description

Bibliographic Details
Main Authors:	Carolina A. Isnardi, Emma Civit, Agustín García Ciccarelli, Jimena Sánchez Alcover, Sebastián Magri, Rodrigo García Salinas, Eduardo Albiero, Carla Gobbi, Edson Velozo, Enrique R. Soriano, Martín Brom, Johana Zacariaz, Ingrid Strusberg, Marcos Baravalle, Sol Castaños, Liliana Morales, Sergio Paira, Romina Calvo, Alberto Ortiz, Rodolfo Pérez Alamino, Hernán Maldonado Ficco, Gustavo Citera
Format:	Article
Language:	English
Published:	Sociedad Argentina de Reumatologia 2021-06-01
Series:	Revista Argentina de Reumatología
Subjects:	golimumab inhibidor de TNFα eficacia seguridad sobrevida
Online Access:	https://ojs.reumatologia.org.ar/index.php/revistaSAR/article/view/358

Similar Items

Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials
by: Toussirot E, et al.
Published: (2016-07-01)

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
by: Proton Rahman, et al.
Published: (2020-09-01)

Golimumab Therapy in Ulcerative Colitis
by: Won Moon
Published: (2016-02-01)

GOLIMUMAB — A NEW TNF α-BLOCKER. THE REVIEW OF THE EFFICACY AND SAFETY EVALUATION RESULTS
by: R. V. Denisova, et al.
Published: (2012-07-01)

Golimumab (anti-TNF monoclonal antibody): where we stand today
by: Ana Teresa Melo, et al.
Published: (2021-06-01)

Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis
by: Pugliese D, et al.
Published: (2016-02-01)

Tolerancia, sobrevida y adherencia al tratamiento con Metotrexato en pacientes con artritis reumatoidea
by: J.M. Sevillano Gutierrez, et al.
Published: (2019-06-01)

Golimumab in the treatment of psoriatic arthritis: efficacy and safety
by: Tatiana Viktorovna Korotaeva, et al.
Published: (2015-09-01)

Dose Adjustment of Methotrexate Administered Concomitantly with Golimumab for Rheumatoid Arthritis in Japanese Real-World Clinical Settings
by: Fumiko Yamairi, et al.
Published: (2020-08-01)

Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
by: Jongwook Yu, et al.
Published: (2022-09-01)

Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
by: Sofia Lanz, et al.
Published: (2021-08-01)

Exposure to golimumab during pregnancy: Results from the Company's global safety database
by: Marijo Otero‐Lobato, et al.
Published: (2024-08-01)

Efficacy of golimumab in treating uveitis in patients with ankylosing spondylitis
by: T. V. Dubinina, et al.
Published: (2016-09-01)

The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
by: Natalia Vladimirovna Chichasova
Published: (2014-12-01)

Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis
by: Kichul Shin, et al.
Published: (2022-09-01)

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis
by: Jeffrey R. Curtis, et al.
Published: (2019-12-01)

Artritis reumatoidea
by: Enrique Soriano
Published: (2013-12-01)

Efficacy of golimumab in the treatment of patients with ankylosing spondylitis (according to the data of a long-term follow-up)
by: A. V. Smirnov, et al.
Published: (2015-03-01)

Adherence to treatment with adalimumab, golimumab and ustekinumab in patients with inflammatory bowel disease
by: María Calvo-Arbeloa, et al.
Published: (2020-03-01)

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
by: M. Rossini, et al.
Published: (2015-03-01)

Association Between Nursing Support Levels and Effectiveness of Golimumab in the Management of Patients with Rheumatologic Diseases
by: Hermine Leroi, et al.
Published: (2020-05-01)

Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
by: Shiro Nakamura, et al.
Published: (2022-07-01)

Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry
by: Proton Rahman, et al.
Published: (2020-11-01)

Time course of changes in the clinical and instrumental manifestations of coxitis in patients with ankylosing spondylitis during golimumab therapy: a GO-COX study. Preliminary results
by: Sh. Erdes, et al.
Published: (2019-07-01)

Patrones de tratamiento con agentes biológicos. Eficacia y sobrevida a largo plazo en pacientes con artritis reumatoidea
by: R. Rolón Campuzano, et al.
Published: (2018-12-01)

A case of idiopathic necrotizing scleritis with secondary glaucoma treated successfully with golimumab and Ahmed valve implantation
by: Parthopratim Dutta Majumder, et al.
Published: (2019-01-01)

Paradoxical Reaction to Golimumab: Tumor Necrosis Factor α Inhibitor Inducing Psoriasis Pustulosa
by: Marien Siqueira Soto Lopes, et al.
Published: (2013-11-01)

Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study
by: Atul Deodhar, et al.
Published: (2023-06-01)

A Real-World Claims Database Study Assessing Long-Term Persistence with Golimumab Treatment in Patients with Rheumatoid Arthritis in Japan
by: Masahiko Miyashiro, et al.
Published: (2023-02-01)

Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age
by: John Tesser, et al.
Published: (2019-08-01)

Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab
by: Ellis LA, et al.
Published: (2019-01-01)

Long-term results of golimumab therapy for rheumatoid arthritis. Therapy compliance issues
by: N. V. Chichasova
Published: (2016-06-01)

Successful Response to Golimumab in a Case of Relapsing Polychondritis Overlapping with Ulcerative Colitis
by: Kojima S, et al.
Published: (2024-01-01)

Early identification of golimumab-treated patients with higher likelihood of long-term retention
by: Alicia García-Dorta, et al.
Published: (2024-04-01)

Golimumab for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: Pharmacologic and Clinical Considerations
by: Sydney Moore McIntosh, et al.
Published: (2023-07-01)

Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study
by: Vermeire S, et al.
Published: (2018-07-01)

Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases
by: Manuel Pombo-Suárez, et al.
Published: (2023-06-01)

Golimumab in the treatment of extra-skeletal manifestations of ankylosing spondylitis
by: A. B. Demina
Published: (2019-10-01)

EFFECT OF GOLIMUMAB ON IMMUNOLOGICAL MARKERS FOR BONE METABOLISM AND ON ARTERIAL STIFFNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: L. A. Knyazeva, et al.
Published: (2018-07-01)

Effects of Golimumab and Ustekinumab on Circulating Dendritic Cell Migratory Capacity in Inflammatory Bowel Disease
by: Irene Soleto, et al.
Published: (2023-10-01)